Shining Light on AAVs: Using Light Scattering Technologies to Solve Challenges in Characterization
With the rising clinical and commercial successes of AAV-based gene therapies, there is an ever-growing demand for robust, platform analytical technologies that can help ensure better product quality, safety, and efficacy.
Size exclusion chromatography (SEC) and Field Flow Fractionation (FFF), coupled with multi-angle light scattering technologies (MALS), are rapidly emerging as transformative technologies for rapid and accurate characterization of AAV samples. Critical Quality Attributes (CQAs) such as capsid titer, genome titer, empty/full, % aggregation and purity of various AAV serotypes can all be obtained in a single measurement. This multi-attribute approach dramatically reduces operational costs and reduces drug development timelines.
Key Learning Objectives:
See how SEC-MALS compares to orthogonal techniques (ddPCR, Capsid ELISA’s, and AUC) for the characterization of AAV during various downstream steps
Understand how light scattering can be used as a rapid screening tool when working with multiple AAV serotypes
Appreciate the value of FFF-MALS for accurate, AAV aggregation analysis
Who Should Attend:
Academic researchers involved in biophysical studies
Academic researchers involved in gene therapy studies
Gene Therapy - Discovery
Gene Therapy - Development
Gene Therapy – QC
Government researchers involved in gene therapy research
Presenter: Steven Milian, M.S. (Sr. Staff Scientist, Research & Development Dept. of Patheon (by Thermo Fisher Scientific) Viral Vector Services)
Presenter: Gennarino Del Bagno, B.S. (Lead Scientist, Research & Development Dept. of Patheon (by Thermo Fisher Scientific) Viral Vector Services)
Presenter: Sophia Kenrick, Ph.D. (Director of Analytical Sciences, Waters|Wyatt Technology)
Presenter: Melissa O'Meara (Forensic Science Consultant, C&EN Media Group)
